UPDATE 1-Spring Bank stops hepatitis drug development after patient dies during trial
January 29, 2020 at 09:25 AM EST
Shares of Spring Bank Pharmaceuticals plummeted 26% on Wednesday after the company said it would end the development of an experimental drug to treat chronic hepatitis B virus, following the death of a patient in a mid-stage trial.